Precision at the Point of Injury

Biomaterials that
heal, seal,
and protect.

Arogya Biotechnologies engineers next-generation biomaterials for critical unmet needs in surgery and wound care. Our first platform, HemoSeal, addresses life-threatening surgical bleeding where current sealants fall short.

Explore HemoSeal → Investor Inquiries
ANTIBACTERIAL ELASTIC WOUND SEALING HEMORRHAGE CONTROL INJECTABLE
The Challenge

Surgical bleeding
is a solved problem—
except when it isn't.

Uncontrolled hemorrhage is a leading cause of preventable death in surgery and trauma. Existing hemostatic sealants work in controlled settings but fail in wet, dynamic, or infected tissue environments where they are needed most.

$3B+
Global surgical sealant market, projected to exceed $4.6B by 2030
30%
Trauma deaths attributable to uncontrolled hemorrhage
~500K
High-risk abdominal and thoracic surgeries in the US annually
$0
Currently approved antibacterial sealants for infected wound fields
  • 01
    Poor wet adhesion. Leading sealants wash away in actively bleeding fields, requiring surgeons to temporarily halt blood flow before application—a significant limitation in emergent scenarios.
  • 02
    No antibacterial activity. None of the currently approved sealants address the risk of post-operative infection at the wound site, a leading driver of surgical complications and hospital costs.
  • 03
    Mechanical mismatch. Rigid or brittle sealants fail at the interface with elastic tissues like lung, bowel, and vascular structures, leading to rebleeding and sealant detachment.
  • 04
    Limited minimally invasive access. Most sealants cannot be injected through standard laparoscopic or endoscopic ports, restricting their utility in the fastest-growing segment of surgery.
Our Solution

Introducing HemoSeal

Nature-Inspired Design
HemoSeal draws inspiration from how marine organisms adhere to wet surfaces in the ocean — achieving strong, reliable bonding even in the most challenging biological environments.
What It Is
A next-generation injectable hemostatic sealant designed to stop bleeding, prevent infection, and conform to the body's tissues — all from a single material.

Published: Advanced Science, 2025

HemoSeal is a multifunctional hemostatic sealant that goes beyond what any single approved product offers today. Engineered at the intersection of hemostasis, infection control, and mechanical compliance, it is designed to perform where current sealants fail.

  • Strong wet-tissue adhesion — bonds reliably to actively bleeding tissue without requiring a dry operative field
  • Broad-spectrum antibacterial activity — inhibits bacterial growth without relying on antibiotics, reducing the risk of post-operative infection
  • Mechanically matched to soft tissue — elastic and flexible, conforming to dynamic anatomical structures such as lung, bowel, and vasculature
  • Injectable and minimally invasive — deliverable through standard laparoscopic or endoscopic ports for use in modern surgical workflows
  • Biodegradable and biocompatible — designed to safely resorb over time with a favorable safety profile
Market Opportunity

A focused path
to a large market

HemoSeal enters the surgical sealant market through a defined beachhead in high-risk abdominal surgery, then expands across thoracic, trauma, and minimally invasive procedures.

TAM — Global Surgical Sealants
$3.2B (2024)
SAM — US Abdominal + Thoracic
$850M
SOM — Year 1–5 Target
$85M

Development Milestones

  • Complete
    In vitro hemostasis, adhesion, and antibacterial validation. Published in Advanced Science (2025). USPTO provisional filed.
  • $1.5M Seed
    GLP pre-clinical studies (rodent and porcine models). FDA IDE pre-submission meeting. Scale-up and sterile formulation development.
  • Series A
    IND filing, Phase I/II first-in-human study. Manufacturing partnership for clinical-grade material.
  • Path to FDA
    510(k) De Novo pathway. Primary endpoint: hemostasis at 4 minutes intra-operatively.
Team

Science-first.
Mission-driven.

SJ
Saumya Jain, PhD
Founder & CEO

PhD in Chemical Engineering, UCLA (Annabi Biomaterials Lab). Inventor of the HemoSeal platform technology. 14 peer-reviewed publications including first-author papers in Science Translational Medicine and Advanced Science. Two filed patents. Deep expertise in hydrogel design, nanoparticle drug delivery, and tissue engineering.

UCLAPhD, Chem. Engineering
14Peer-reviewed publications
2Filed patents
STMFirst-author, 2025

Scientific & Clinical Advisors

Prof. Nasim Annabi, PhD
Scientific Advisor & PhD Supervisor · Associate Professor of Chemical Engineering, UCLA · Director, Annabi Biomaterials & Bioengineering Lab · Co-founder, GelMEDIX · Pioneer in photo-crosslinkable hydrogels for cardiovascular, pulmonary, and wound-healing applications, with over 100 peer-reviewed publications and multiple FDA-track technologies in development
Dr. George Cheng, MD/PhD
Clinical Advisor · Interventional Pulmonologist & Assistant Professor of Medicine, UC San Diego · Co-founder, Restor3d · Specialist in bronchoscopic and minimally invasive thoracic procedures, with deep expertise in the clinical unmet needs surrounding airway and pulmonary hemorrhage — the primary target indication for HemoSeal's first-in-human study
Seeking

$1.5M seed financing to fund GLP pre-clinical studies, FDA IDE pre-submission, and formulation scale-up. Targeting first close Q3 2025. Strategic investors with medtech, biosurgery, or trauma care expertise are prioritized.

Request Deck →
Get In Touch

Partner with us to stop preventable bleeding.

We are actively building relationships with strategic investors, clinical collaborators, and medtech partners who share our vision for better surgical outcomes.

Contact the Founder → Read the Publication